Denali Therapeutics Inc. DNLI Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
Based on trailing twelve months.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s return on equity?
- Denali Therapeutics Inc. (DNLI) reported return on equity of -49.6% in Q1 2026.
- How has Denali Therapeutics Inc.'s return on equity changed year-over-year?
- Denali Therapeutics Inc.'s return on equity decreased by 40.8% year-over-year, from -35.2% to -49.6%.
- What is the long-term trend for Denali Therapeutics Inc.'s return on equity?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s return on equity has grown at a 37.8% compound annual growth rate (CAGR), from 9.2% to -45.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.